PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 30, 2025Frontiers in Immunology11 citationsOpen Access

RIPK1 signaling pathways: implications for autoimmune and neuroinflammatory diseases

View Full Paper
APAbigail PajulasJSJonathan T. SimsEHEric P. Hanson

Key Points

  • RIPK1 influences inflammation and cell death, showing potential as a therapeutic target in autoimmune diseases.
  • Recent findings indicate RIPK1's critical roles in necroptosis and immune cell regulation across various conditions.
  • The review discusses the complex signaling pathways of RIPK1, emphasizing its tissue-specific and cell type effects.
  • Therapeutic strategies targeting RIPK1 could offer new avenues for treating neuroinflammatory and autoimmune disorders.

Abstract

Receptor-interacting protein kinase 1 (RIPK1), which regulates cell death and survival pathways, is a promising therapeutic target for the treatment of several autoimmune, inflammatory, and neurodegenerative diseases, having important roles in inflammation, apoptosis, and necroptosis. In this review, we describe recent insights that help elucidate the molecular mechanisms of signaling pathways reliant on RIPK1, focusing on its scaffolding function and kinase activity. We emphasize the cell type-specific effects of RIPK1, characterizing its role in necroptosis, immune cell regulation, and tissue-specific responses. Lastly, we present the relevance of RIPK1 in autoimmune and inflammatory diseases, while highlighting the clinical landscape for RIPK1-targeting therapies. All together, this review aims to present recent findings pertaining to RIPK1 signaling and discuss its potential as a therapeutic target in diseases.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Pajulas et al. (2025) studied this question.

synapsesocial.com/papers/68dc12d38a7d58c25ebb10f0https://doi.org/10.3389/fimmu.2025.1642593
Ask AI
Helpful
Bookmark
Share
View Full Paper